Zika Fever disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MedlinePlus: ⁴¹ Zika is a virus that is spread mostly by mosquitoes. A pregnant mother can pass it to her baby during pregnancy or around the time of birth. It can spread through sexual contact. There have also been reports that the virus has spread through blood transfusions. There have been outbreaks of Zika virus in the United States, Africa, Southeast Asia, the Pacific Islands, parts of the Caribbean, and Central and South America. Most people who get the virus do not get sick. One in five people do get symptoms, which can include a fever, rash, joint pain, and conjunctivitis (pink eye). Symptoms are usually mild, and start 2 to 7 days after being bitten by an infected mosquito. A blood test can tell whether you have the infection. There are no vaccines or medicines to treat it. Drinking lots of fluids, resting, and taking acetaminophen might help. Zika can cause microcephaly (a serious birth defect of the brain) and other problems in babies whose mothers were infected while pregnant. The Centers for Disease Control and Prevention recommends that pregnant women do not travel to areas where there is a Zika virus outbreak. If you do decide to travel, first talk to your doctor. You should also be careful to prevent mosquito bites: Use insect repellent Wear clothes that cover your arms, legs, and feet Stay in places that have air conditioning or that use window and door screens Centers for Disease Control and Prevention

MalaCards based summary: Zika Fever, also known as zika virus infection, is related to torch syndrome and st. louis encephalitis, and has symptoms including fever, rash and headaches. An important gene associated with Zika Fever is DNAAF2 (Dynein Axonemal Assembly Factor 2), and among its related pathways/superpathways are SARS-CoV-2 Infection and NF-kappaB Signaling. The drugs Aluminum hydroxide and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and placenta, and related phenotypes are maculopapular exanthema and arthritis

GARD: ¹⁹ Zika virus infection is spread to people primarily through the bite of an infected mosquito. Zika virus can also be spread from a pregnant mother to her child and through sexual contact with an affected partner. Cases of Zika virus transmission via blood transfusion have also been reported. Zika virus outbreaks are currently occurring in many countries. The illness associated with Zika virus infection is usually mild, with symptoms lasting for several days to a week. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). The full range of health problems associated with Zika virus infection during pregnancy is currently being studied. No vaccine currently exists to prevent Zika virus infection, but there are still ways to protect oneself. The CDC recommends that pregnant women consider postponing travel to Zika-affected areas. People living in or traveling to areas where Zika virus is found should take steps to prevent mosquito bites. Those who have traveled to Zika-affected areas may wish to take steps to prevent sexual transmission of the Zika virus.

Orphanet: ⁵⁸ Zika virus disease is an emerging Aedes mosquito-born virus disease characterized by a clinical course that may be asymptomatic or mild with fever, conjunctivitis, muscle and joint pain, headache, exanthema, but may also be associated with severe neurological (meningitis, meningoencephalitis and myelitis) and auto-immune (Guillain-Barre syndrome) complications, as well as a potential increase of birth defects (microcephaly) if the infection occurs during pregnancy.

CDC: ² Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). These mosquitoes bite during the day and night. Zika can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause certain birth defects. There is no vaccine or medicine for Zika.

Disease Ontology: ¹¹ A viral infectious disease that has material basis in Zika virus, which is transmitted by Aedes aegypti mosquitoes and targets neural progenitor cells and neuronal cells in all stages of maturity and has symptom fever, has symptom rash, has symptom headaches and has symptom joint pain.

Wikipedia ⁷⁵ Zika fever: Zika fever, also known as Zika virus disease or simply Zika, is an infectious disease caused by the Zika... more...

Zika virus: Zika virus (ZIKV; pronounced /ˈziːkə/ or /ˈzɪkə/) is a member of the virus family Flaviviridae. It is... more...

Sources

Related Diseases for Zika Fever

Diseases related to Zika Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 492)

#	Related Disease	Score	Top Affiliating Genes
1	torch syndrome	31.6	STAT2 IFNAR1
2	st. louis encephalitis	30.1	IFNA1 ERVW-1
3	acute retrobulbar neuritis	30.1	SH2D3A IFNB1
4	lymphocytic choriomeningitis	30.0	TYRO3 RIGI CD209 AXL
5	chikungunya	29.9	TLR3 RIGI FURIN CD209
6	yellow fever	29.8	RIGI IFNB1 IFNAR1
7	hantavirus pulmonary syndrome	29.8	RIGI IFNB1 ERVW-1
8	stomatitis	29.8	RIGI IFNB1 IFNA1
9	dengue virus	29.7	STAT2 RIGI CD209
10	viral encephalitis	29.7	TLR3 RIGI IFNB1 IFNAR1 IFNA1
11	encephalitis	29.7	TLR3 RIGI IFNB1 IFNA1 ERVW-1 CD209
12	middle east respiratory syndrome	29.6	SH2D3A IFNB1 FURIN
13	rubella	29.6	TLR3 RIGI IFNB1
14	west nile virus	29.6	RIGI IFNA1 CD209
15	vaccinia	29.6	STAT2 IFNB1 IFNA1 ERVW-1
16	poliomyelitis	29.6	TLR3 RIGI IFNB1 IFNA1
17	chickenpox	29.4	TLR3 IFNB1 IFNA1
18	crimean-congo hemorrhagic fever	29.2	IFNB1 IFNAR1 IFNA1 ERVW-1
19	tick-borne encephalitis	29.2	TLR3 SH2D3A IFNAR1 IFNA1 FURIN ERVW-1
20	mouth disease	29.2	TLR3 RIGI IFNA1 CD209
21	thrombocytopenia	29.2	STAT2 RIGI IFNB1 IFNA1 CD209
22	dengue disease	29.1	RIGI IFNB1 IFNAR1 IFNA1 FURIN ERVW-1
23	lassa fever	29.0	RIGI IFNB1 IFNAR1 IFNA1 ERVW-1 CD209
24	immune deficiency disease	29.0	IFNB1 IFNA1 FURIN ERVW-1 CD209
25	rabies	29.0	TLR3 STAT2 RIGI IFNA1
26	measles	29.0	TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
27	respiratory failure	28.9	TLR3 IFNB1 IFNA1 FURIN
28	influenza	28.8	TLR3 RIGI IFNB1 IFNA1 FURIN
29	dengue hemorrhagic fever	28.7	STAT2 RIGI IFNAR1 IFNA1 FURIN ERVW-1
30	multiple sclerosis	28.7	TLR3 IFNB1 IFNAR1 IFNA1 ERVW-1
31	severe acute respiratory syndrome	28.7	SH2D3A RIGI IFNB1 IFNA1 FURIN CD209
32	dengue shock syndrome	28.7	STAT2 RIGI IFNA1 FURIN ERVW-1 CD209
33	herpes simplex	28.7	TLR3 STAT2 RIGI IFNB1 IFNA1 CD209
34	mumps	28.6	TLR3 STAT2 IFNB1 IFNA1 FURIN
35	nervous system disease	28.6	TLR3 RIGI IFNB1 IFNAR1 IFNA1 AXL
36	west nile encephalitis	28.5	TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
37	avian influenza	28.4	TLR3 RIGI IFNB1 IFNA1 FURIN ERVW-1
38	west nile fever	28.3	TLR3 RIGI IFNB1 IFNAR1 IFNA1 FURIN
39	viral infectious disease	28.2	TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
40	ebola hemorrhagic fever	28.0	TLR3 SH2D3A RIGI IFNB1 IFNAR1 IFNA1
41	japanese encephalitis	27.7	TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
42	zika virus congenital syndrome	11.3
43	hydrocephalus, congenital, 1	10.7
44	distal arthrogryposis	10.5
45	hydrocephalus	10.4
46	cerebellar atrophy, developmental delay, and seizures	10.4
47	lissencephaly	10.4
48	neuroblastoma	10.4
49	toxoplasmosis	10.4
50	brain cancer	10.3

Graphical network of the top 20 diseases related to Zika Fever:

Sources

Symptoms & Phenotypes for Zika Fever

Human phenotypes related to Zika Fever:

⁵⁸ ³⁰ (show all 36)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	maculopapular exanthema ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0040186
2	arthritis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001369
3	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001945
4	arthralgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002829
5	myalgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003326
6	conjunctivitis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000509
7	headache ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002315
8	pruritus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000989
9	increased circulating igm level ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003496
10	abnormality of the cerebrospinal fluid ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002921
11	vomiting ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002013
12	edema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000969
13	wrist swelling ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001225
14	ankle swelling ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001785
15	transient hearing impairment ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012779
16	microcephaly ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000252
17	intrauterine growth retardation ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001511
18	thrombocytopenia ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001873
19	lens subluxation ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001132
20	iris coloboma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000612
21	meningitis ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001287
22	subcutaneous hemorrhage ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001933
23	optic disc hypoplasia ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0007766
24	macular atrophy ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0007401
25	retinal pigment epithelial mottling ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0007814
26	chorioretinal atrophy ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000533
27	myelitis ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0012486
28	acute demyelinating polyneuropathy ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0007131
29	absent foveal reflex ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0030825
30	congenital intracerebral calcification ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0006906
31	infectious encephalitis ³⁰	Very rare (1%)		HP:0002383
32	abnormal optic disc morphology ³⁰	Very rare (1%)		HP:0012795
33	encephalitis ⁵⁸		Very rare (<4-1%)
34	skin rash ⁵⁸		Very frequent (99-80%)
35	spontaneous abortion ⁵⁸		Very rare (<4-1%)
36	abnormality of the optic disc ⁵⁸		Very rare (<4-1%)

Symptoms:

¹¹

• fever
• rash

• headaches
• joint pain

Sources

Drugs & Therapeutics for Zika Fever

Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Aluminum hydroxide

Approved, Investigational

Phase 2

21645-51-2

2

Pharmaceutical Solutions

Phase 2

3

Immunologic Factors

Phase 2

4

Vaccines

Phase 2

5

Aluminum sulfate

Approved

Phase 1

10043-01-3

6

Immunoglobulins, Intravenous

Phase 1

7

Immunoglobulin G

Phase 1

8

Antibodies, Blocking

Phase 1

9

gamma-Globulins

Phase 1

10

Rho(D) Immune Globulin

Phase 1

11

Amphotericin B

Approved, Investigational

1397-89-3

5280965

12

Streptomycin

Approved, Vet_approved

57-92-1

19649

13

L-Glutamine

Approved, Investigational, Nutraceutical

56-85-9

5961

14

Pyruvate

15

Penicillins

16

Gentamicins

17

Liposomal amphotericin B

Interventional clinical trials:

(show top 50) (show all 55)

#	Name	Status	NCT ID	Phase	Drugs
1	Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study	Recruiting	NCT03037164	Phase 3
2	VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents	Completed	NCT03110770	Phase 2
3	A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas	Active, not recruiting	NCT04917861	Phase 2
4	A Phase 2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of the Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Day 1 and 29 and of a Single Booster Dose of PIZV Administered at 6 Months Post Dose 2 in Healthy Subjects Aged 18 to 65 Years in the US	Not yet recruiting	NCT05469802	Phase 2
5	A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region	Completed	NCT03014089	Phase 1
6	Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area	Completed	NCT03008122	Phase 1
7	VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults	Completed	NCT02996461	Phase 1
8	Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers	Completed	NCT02996890	Phase 1
9	Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects	Completed	NCT02952833	Phase 1	Saline
10	A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects	Completed	NCT02963909	Phase 1
11	A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years	Completed	NCT03343626	Phase 1	Placebo
12	Phase 1, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate 2 Doses of 3 Sequentially Escalating Cohort of BBV121 in Healthy Adult Dengue Sero-Negative and Dengue Sero-Positive Volunteers	Completed	NCT04478656	Phase 1
13	Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP	Completed	NCT04033068	Phase 1
14	A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years	Completed	NCT03425149	Phase 1
15	Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers	Completed	NCT03624946	Phase 1
16	Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults	Completed	NCT03611946	Phase 1
17	A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults	Completed	NCT04064905	Phase 1
18	A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults	Completed	NCT02937233	Phase 1
19	VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults	Completed	NCT02840487	Phase 1
20	Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers	Completed	NCT03443830	Phase 1	Tyzivumab
21	A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers.	Completed	NCT04015648	Phase 1
22	Phase I Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)	Recruiting	NCT05123222	Phase 1
23	Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients	Withdrawn	NCT03776695	Phase 1
24	Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua	Unknown status	NCT04182685
25	Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome	Unknown status	NCT03227601
26	Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016	Unknown status	NCT02810210
27	Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF	Unknown status	NCT03255369
28	Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy	Unknown status	NCT02943304
29	Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA	Completed	NCT03776903
30	Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome	Completed	NCT03330600
31	Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During the First or Second Trimester of Gestation.	Completed	NCT03679728
32	Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil	Completed	NCT03106714
33	Persistence of Zika Virus in Semen After Acute Infection	Completed	NCT02733796
34	Rescuing Neurodevelopment in Zika-Exposed Infants in Grenada	Completed	NCT04697147
35	Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors	Completed	NCT02794181
36	Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection	Completed	NCT02979938
37	Prospective Cohort Study of HIV and Zika in Infants and Pregnancy	Completed	NCT03263195
38	Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy	Completed	NCT03393286
39	World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia	Completed	NCT03631719
40	Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia	Completed	NCT03206541
41	Pregnant Women (PW) Cohort for Evaluation of Risks of Congenital Malformations and Other Adverse Pregnancy Outcomes After Zika Virus Infection (Part of ZIKAlliance)	Completed	NCT03188731
42	Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine	Completed	NCT03158233
43	The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01)	Completed	NCT02831699
44	Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016	Completed	NCT02916732
45	International Prospective Observational Cohort Study of Zika in Infants	Completed	NCT02856984
46	Pilot Study to Detect Zika Virus in Sperm	Completed	NCT02874456
47	The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy	Completed	NCT04118738
48	Adherence to Care for Children Born to Mothers With Laboratory Evidence of Confirmed or Possible Congenital Zika Virus Infection During Pregnancy.	Recruiting	NCT05041439
49	Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.	Recruiting	NCT01099852
50	Developmental Outcome After In Utero ZIKV Exposure in Children Without Congenital Zika Syndrome	Enrolling by invitation	NCT04398901

Search NIH Clinical Center for Zika Fever

Cochrane evidence based reviews: zika virus infection

Sources

Genetic Tests for Zika Fever

Sources

Anatomical Context for Zika Fever

Organs/tissues related to Zika Fever:

MalaCards : Brain, Eye, Placenta, Skin, Fetal Brain, T Cells, Whole Blood

Sources

Publications for Zika Fever

Articles related to Zika Fever:

(show top 50) (show all 7697)

#	Title	Authors	PMID	Year
1	Zika virus noncoding RNA cooperates with the viral protein NS5 to inhibit STAT1 phosphorylation and facilitate viral pathogenesis. ⁶² ⁴¹	Slonchak A...Khromykh AA	36449607	2022
2	Type I interferon receptor (IFNAR2) deficiency reveals Zika virus cytopathicity in human macrophages and microglia. ⁶² ⁴¹	Hanrath AT...Duncan CJA	36439115	2022
3	In silico and in vitro arboviral MHC class I-restricted-epitope signatures reveal immunodominance and poor overlapping patterns. ⁴¹	Lopes-Ribeiro A...Coelho-Dos-Reis JGA	36466864	2022
4	Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies. ⁶²	Davies AJ...Rinaldi S	36411078	2023
5	Identification of an N-phenylsulfonyl-2-(piperazin-1-yl)methyl-benzonitrile derivative as Zika virus entry inhibitor. ⁶²	Quan Y...Cen S	36417826	2023
6	Methodological procedures explain observed differences in the competence of European populations of Aedes albopictus for the transmission of Zika virus. ⁶²	Gutierrez-Lopez R...Martinez-de la Puente J	36270381	2023
7	Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage. ⁶²	Marchi S...Trombetta CM	36374844	2023
8	Sensitive Zika biomarker detection assisted by quantum dot-modified electrochemical immunosensing platform. ⁶²	Ribeiro JFF...Fontes A	36371925	2023
9	3D Structural Analysis of Long Noncoding RNA by Small Angle X-ray Scattering and Computational Modeling. ⁶²	Zhang J...Fang X	36227567	2023
10	An Automated Strategy to Handle Antigenic Variability in Immunisation Protocols, Part I: Nanopore Sequencing of Infectious Agent Variants. ⁶²	Pereira GC	36301483	2023
11	A peptide derived from the N-terminal of NS2A for the preparation of ZIKV NS2A recognition polyclonal antibody. ⁶²	Yu Y...Zou P	36463933	2022
12	An update on teratogens for pediatric healthcare providers. ⁶²	Valladares DA...Rasmussen SA	36081369	2022
13	Development and evaluation of a visible reverse transcription-loop-mediated isothermal amplification (RT-LAMP) for the detection of Asian lineage ZIKV in field-caught mosquitoes. ⁶²	Siriyasatien P...Phumee A	36103950	2022
14	Scramblases and virus infection. ⁶²	Tang D...Qi S	36285664	2022
15	Role of Necroptosis in Central Nervous System Diseases. ⁶²	Shao H...Zhuang C	36373337	2022
16	Emerging quinoline- and quinolone-based antibiotics in the light of epidemics. ⁶²	Kaur P...Mittal A	35128812	2022
17	Recent trends and advancements in electrochemiluminescence biosensors for human virus detection. ⁶²	Sobhanie E...Hanif S	35815064	2022
18	Transcriptional and post-transcriptional mechanisms that regulate the genetic program in Zika virus-infected macrophages. ⁶²	Fernandez GJ...Urcuqui-Inchima S	36257579	2022
19	Influence of Zika virus 3'-end sequence and nonstructural protein evolution on the viral replication competence and virulence. ⁶²	Jung HG...Oh JW	36149812	2022
20	Evaluation of Zika virus DNA vaccines based on NS1 and domain III of E. ⁶²	Xiong G...Chen H	36274487	2022
21	Transcriptome profiling and Calreticulin expression in Zika virus -infected Aedes aegypti. ⁶²	de Almeida LS...Suesdek L	36473637	2022
22	GPI-anchored ligand-BioID2-tagging system identifies Galectin-1 mediating Zika virus entry. ⁶²	Gao SS...Li C	36404916	2022
23	Immunological imbalance in microcephalic children with congenital Zika virus syndrome. ⁶²	Salmeron ACA...Nascimento MSL	35857104	2022
24	Simultaneous exposure to both Zika virus and household insecticides during pregnancy, and fetal growth and infant developmental behavior outcomes at 18 months, in Guadeloupe. ⁶²	Kadawathagedara M...Chevrier C	36096163	2022
25	Identification and characterization of key residues in Zika virus envelope protein for virus assembly and entry. ⁶²	Ma X...Yi Z	35612559	2022
26	Neurological evaluation of microcephalic children with Zika syndrome and congenital cytomegalovirus infection. ⁶²	Faccini LS...da Silva Inacio de Bone S	36164338	2022
27	The RNA polymerase of cytoplasmically replicating Zika virus binds with chromatin DNA in nuclei and regulates host gene transcription. ⁶²	Li P...Guo D	36442102	2022
28	Zika virus infects human osteoclasts and blocks differentiation and bone resorption. ⁶²	Mumtaz N...Rockx B	35670284	2022
29	Discovery of dehydroandrographolide derivatives with C19 hindered ether as potent anti-ZIKV agents with inhibitory activities to MTase of ZIKV NS5. ⁶²	Qian W...Zhou GC	36055002	2022
30	Intrauterine Zika virus infection: review of the current findings with emphasis in the prenatal and postnatal brain imaging diagnostic methods. ⁶²	Santana EFM...Araujo Junior E	33781162	2022
31	My child is growing and now? Exploring the environmental needs of children with congenital Zika syndrome according to their caregivers' perceptions. ⁶²	Coelho MLG...Longo E	36281641	2022
32	RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region. ⁶²	Yao Y...Pei R	36464077	2022
33	Vaccination with a Zika virus envelope domain III protein induces neutralizing antibodies and partial protection against Asian genotype in immunocompetent mice. ⁶²	Shin M...Hahn TW	36471432	2022
34	Multiplexed rapid antigen tests developed using multicolored nanoparticles and cross-reactive antibody pairs: Implications for pandemic preparedness. ⁶²	de Puig H...Gehrke L	36348742	2022
35	Re-emergence of dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. ⁶²	Ushijima Y...Yasuda J	36200059	2022
36	Unraveling the Metabolic Alterations Induced by Zika Infection in Prostate Epithelial (PNT1a) and Adenocarcinoma (PC-3) Cell Lines. ⁶²	Delafiori J...Catharino RR	36469742	2022
37	Aerosolized Zika virus infection in Guinea pigs. ⁶²	Qiu HY...Zhou DS	36069671	2022
38	Spatial, Sociodemographic, and Weather Analysis of the Zika Virus Outbreak: U.S. Virgin Islands, January 2016-January 2018. ⁶²	Browne AS...Ellis EM	36399688	2022
39	Estimating Zika virus attack rates and risk of Zika virus-associated neurological complications in Colombian capital cities with a Bayesian model. ⁶²	Charniga K...Donnelly CA	36465672	2022
40	Preclinical evaluation of [¹⁸F]FDG-PET as a biomarker of lymphoid tissue disease and inflammation in Zika virus infection. ⁶²	Victorio CBL...Chacko AM	35876869	2022
41	Repurposing of the antihistamine mebhydrolin napadisylate for treatment of Zika virus infection. ⁶²	Zhou R...Cen S	35901544	2022
42	Offspring affected with in utero Zika virus infection retain molecular footprints in the bone marrow and blood cells. ⁶²	Udenze D...Karniychuk U	36369716	2022
43	Zika Virus Infection Downregulates Connexin 43, Disrupts the Cardiomyocyte Gap Junctions and Induces Heart Diseases in A129 Mice. ⁶²	Li S...Tang Q	36226984	2022
44	Folic acid-functionalized graphene quantum dots: Synthesis, characterization, radiolabeling with radium-223 and antiviral effect against Zika virus infection. ⁶²	Pijeira MSO...Santos-Oliveira R	36154904	2022
45	Testosterone protects mice against zika virus infection and suppresses the inflammatory response in the brain. ⁶²	Zheng B...Ye J	36304103	2022
46	Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala. ⁶²	Paniagua-Avila A...Asturias EJ	36383617	2022
47	Initial Recognition and Attachment of the Zika Virus to Host Cells: A Molecular Dynamics and Quantum Interaction Approach. ⁶²	Gomez SA...Restrepo A	35951472	2022
48	Repeated Rapid Active Sampling Surveys Demonstrated a Rapidly Changing Zika Seroprevalence among Children in a Rural Dengue-endemic Region in Southwest Guatemala during the Zika Epidemic (2015-2016). ⁶²	Lamb MM...Olson D	36252798	2022
49	Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. ⁶²	Zephyr J...Schiffer CA	36446201	2022
50	Arbovirus Antibody Seroprevalence in the Human Population from Cauca, Colombia. ⁶²	Gil-Mora J...Aguilar PV	36375460	2022

Sources

Genes for Zika Fever

Genes related to Zika Fever (0 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	DNAAF2	Dynein Axonemal Assembly Factor 2	Protein Coding	5.34	DISEASES inferred ¹⁴
2	CD209	CD209 Molecule	Protein Coding	5.33	DISEASES inferred ¹⁴
3	IFNAR1	Interferon Alpha And Beta Receptor Subunit 1	Protein Coding	5.31	DISEASES inferred ¹⁴
4	AXL	AXL Receptor Tyrosine Kinase	Protein Coding	5.29	DISEASES inferred ¹⁴
5	TYRO3	TYRO3 Protein Tyrosine Kinase	Protein Coding	5.25	DISEASES inferred ¹⁴
6	ERVW-1	Endogenous Retrovirus Group W Member 1, Envelope	Protein Coding	5.16	DISEASES inferred ¹⁴
7	CNIH1	Cornichon Family AMPA Receptor Auxiliary Protein 1	Protein Coding	4.98	DISEASES inferred ¹⁴
8	SH2D3A	SH2 Domain Containing 3A	Protein Coding	4.97	DISEASES inferred ¹⁴
9	RIGI	RNA Sensor RIG-I	Protein Coding	4.94	DISEASES inferred ¹⁴
10	MAP7D3	MAP7 Domain Containing 3	Protein Coding	4.93	DISEASES inferred ¹⁴
11	XRN1	5'-3' Exoribonuclease 1	Protein Coding	4.86	DISEASES inferred ¹⁴
12	TLR3	Toll Like Receptor 3	Protein Coding	4.83	DISEASES inferred ¹⁴
13	IFNB1	Interferon Beta 1	Protein Coding	4.79	DISEASES inferred ¹⁴
14	STAT2	Signal Transducer And Activator Of Transcription 2	Protein Coding	4.78	DISEASES inferred ¹⁴
15	FURIN	Furin, Paired Basic Amino Acid Cleaving Enzyme	Protein Coding	4.7	DISEASES inferred ¹⁴
16	IFNA1	Interferon Alpha 1	Protein Coding	4.7	DISEASES inferred ¹⁴
17	DDIT4L	DNA Damage Inducible Transcript 4 Like	Protein Coding	4.68	DISEASES inferred ¹⁴

Sources

Variations for Zika Fever

Sources

Expression for Zika Fever

Search GEO for disease gene expression data for Zika Fever.

Sources

Pathways for Zika Fever

Pathways related to Zika Fever according to GeneCards Suite gene sharing:

(show all 14)

#	Super pathways	Score	Top Affiliating Genes
1	SARS-CoV-2 Infection ⁶⁶ Show member pathways SARS-CoV Infections ⁶⁶ SARS-CoV-2 activates/modulates innate and adaptive immune responses ⁶⁶ SARS-CoV-2-host interactions ⁶⁶	12.97	STAT2 RIGI IFNB1 IFNAR1 IFNA1 FURIN
2	NF-kappaB Signaling ³	12.33	TLR3 STAT2 RIGI IFNA1
3	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.23	TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
4	DDX58/IFIH1-mediated induction of interferon-alpha/beta ⁶⁶ Show member pathways Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of DDX58/IFIH1 signaling ⁶⁶ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁶ Novel intracellular components of RIG-I-like receptor pathway ⁷⁴ SARS-CoV-2 B.1.1.7 variant antagonises innate immune activation ⁷⁴ TRAF3-dependent IRF activation pathway ⁶⁶ TRAF6 mediated IRF7 activation ⁶⁶	12.16	TLR3 RIGI IFNB1 IFNA1
5	Interferon gamma signaling ⁶⁶ Show member pathways Interferon Signaling ⁶⁶ Regulation of IFNG signaling ⁶⁶	12.14	STAT2 RIGI IFNB1 IFNAR1 IFNA1
6	Cytosolic sensors of pathogen-associated DNA ⁶⁶ Show member pathways Cytosolic DNA-sensing pathway ⁷⁴ DEx/H-box helicases activate type I IFN and inflammatory cytokines production ⁶⁶ IkBA variant leads to EDA-ID ⁶⁶ IRF3 mediated activation of type 1 IFN ⁶⁶ IRF3-mediated induction of type I IFN ⁶⁶ LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production ⁶⁶ Regulation by TREX1 ⁶⁶ Regulation of innate immune responses to cytosolic DNA ⁶⁶ RIP-mediated NFkB activation via ZBP1 ⁶⁶ Selenium micronutrient network ⁷⁴ STAT6-mediated induction of chemokines ⁶⁶ STING mediated induction of host immune responses ⁶⁶ ZBP1(DAI) mediated induction of type I IFNs ⁶⁶	12.1	TLR3 RIGI IFNB1 IFNA1
7	Ebola virus infection in host ⁷⁴	11.73	TYRO3 RIGI CD209 AXL
8	Potential therapeutics for SARS ⁶⁶	11.67	STAT2 IFNAR1 FURIN
9	Interferon Pathway ⁶⁴	11.42	STAT2 IFNB1 IFNAR1 IFNA1
10	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.25	IFNB1 RIGI STAT2
11	Host-pathogen interaction of human coronaviruses - interferon induction ⁷⁴ Show member pathways Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics ⁶⁰ SARS coronavirus and innate immunity ⁷⁴ Type I interferon induction and signaling during SARS-CoV-2 infection ⁷⁴	11	TLR3 STAT2 RIGI IFNB1 IFNAR1
12	Immune response to tuberculosis ⁷⁴	10.88	STAT2 IFNAR1
13	Pathways of nucleic acid metabolism and innate immune sensing ⁷⁴	10.73	RIGI IFNB1
14	mRNA vaccine activation of dendritic cell and induction of IFN-1 ⁷⁴	10.46	TLR3 RIGI

Sources

GO Terms for Zika Fever

Biological processes related to Zika Fever according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine-mediated signaling pathway	GO:0019221	10.15	STAT2 IFNB1 IFNAR1 IFNA1
2	defense response to virus	GO:0051607	10.1	IFNA1 IFNB1 RIGI STAT2 TLR3
3	response to virus	GO:0009615	10.04	TLR3 RIGI IFNB1 IFNAR1
4	receptor signaling pathway via JAK-STAT	GO:0007259	10	IFNAR1 IFNB1 STAT2
5	cellular response to virus	GO:0098586	9.97	TLR3 IFNB1 IFNAR1 IFNA1
6	cellular response to interferon-alpha	GO:0035457	9.88	IFNAR1 AXL
7	defense response	GO:0006952	9.88	TLR3 STAT2 IFNB1 IFNA1
8	vagina development	GO:0060068	9.87	TYRO3 AXL
9	ovulation cycle	GO:0042698	9.86	TYRO3 AXL
10	detection of virus	GO:0009597	9.84	TLR3 RIGI
11	cellular response to exogenous dsRNA	GO:0071360	9.8	TLR3 RIGI IFNB1
12	negative regulation of lymphocyte activation	GO:0051250	9.76	TYRO3 AXL
13	type I interferon-mediated signaling pathway	GO:0060337	9.76	STAT2 IFNB1 IFNAR1 IFNA1
14	forebrain cell migration	GO:0021885	9.73	TYRO3 AXL
15	secretion by cell	GO:0032940	9.73	AXL FURIN TYRO3
16	response to exogenous dsRNA	GO:0043330	9.56	TLR3 RIGI IFNB1 IFNA1
17	lymphocyte activation	GO:0046649	9.51	TYRO3 AXL
18	positive regulation of viral life cycle	GO:1903902	9.1	TYRO3 CD209 AXL

Molecular functions related to Zika Fever according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	virus receptor activity	GO:0001618	9.1	TYRO3 CD209 AXL

Sources

Sources for Zika Fever

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: ZKF001 MIFTS: 54	Zika Fever Categories: Infectious diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Zika Fever

Aliases & Classifications for Zika Fever

MalaCards integrated aliases for Zika Fever:

Characteristics:

Prevelance:

Age Of Onset:

Classifications:

External Ids:

Summaries for Zika Fever

Related Diseases for Zika Fever

Diseases related to Zika Fever via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Zika Fever:

Symptoms & Phenotypes for Zika Fever

Human phenotypes related to Zika Fever:

Symptoms:

Drugs & Therapeutics for Zika Fever

Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Cochrane evidence based reviews: zika virus infection

Genetic Tests for Zika Fever

Anatomical Context for Zika Fever

Organs/tissues related to Zika Fever:

Publications for Zika Fever

Articles related to Zika Fever:

Genes for Zika Fever

Genes related to Zika Fever (0 elite genes):

Variations for Zika Fever

Expression for Zika Fever

Pathways for Zika Fever

Pathways related to Zika Fever according to GeneCards Suite gene sharing:

GO Terms for Zika Fever

Biological processes related to Zika Fever according to GeneCards Suite gene sharing:

Molecular functions related to Zika Fever according to GeneCards Suite gene sharing:

Sources for Zika Fever